← Back to OncoGuides
E-E-A-T Clinical Governance

Medical Advisory & Editorial Review Board

The OncoGuides Medical Advisory Board is comprised of board-certified medical oncologists, oncology clinical pharmacists, oncology nurse navigators, and supportive care specialists dedicated to maintaining the highest clinical accuracy and patient safety across our open-access clinical guides.

Board Members & Clinical Leadership

Dr. Elena Vance, MD, PhD

Lead Medical Oncologist & Clinical Trialist

Dr. Vance is a board-certified medical oncologist with over 16 years of academic hospital experience specializing in thoracic oncology, molecular targeted therapies, and early-phase clinical trials. She oversees disease staging algorithms and systemic therapy recommendations across all cancer guides.

Dr. Marcus Sterling, PharmD, BCOP

Oncology Clinical Pharmacist & Drug Toxicity Lead

Dr. Sterling specializes in precision pharmacotherapy, chemotherapy-induced organ toxicities (cardiotoxicity, nephrotoxicity, pneumonitis, CIPN), and patient assistance programs. He directs OncoGuides' medication tapering schedules, drug interaction warnings, and copay assistance navigators.

Sarah Jenkins, MSN, RN, OCN

Oncology Nurse Specialist & Patient Navigation Director

With 14 years of clinical oncology nursing experience, Sarah specializes in symptom triage, palliative wound care, patient distress screening, and barrier-reduction for underrepresented oncology patients across North America and Europe.

Dr. Arthur Patel, MD

Supportive Oncology & Palliative Care Physician

Dr. Patel is a specialist in cancer pain management, integrative oncology, and psychosocial comorbidity interventions. He oversees the clinical protocols for psycho-oncology, distress screening, and caregiver support networks.

Our 4-Step Editorial & Peer-Review Process

Strict Evidence-Based Standards

  1. Guideline Grounding: All clinical content is directly synthesized from international consensus guidelines (NCCN, ASCO, ESMO, MASCC, ASTRO, CAP, AMP).
  2. Multidisciplinary Review: Each guide is reviewed by at least one Medical Oncologist and one Board Certified Oncology Pharmacist before publication.
  3. Unslop & Patient Comprehension: Complex molecular pathways and clinical trial data are translated into clear, actionable, jargon-free explanations with transparent biomarker thresholds and survival metrics.
  4. Continuous Audit Cycle: Content is audited quarterly and immediately updated upon new FDA/EMA approvals, black box warnings, or major clinical trial readouts. (Current Audit: August 2026).

Commercial Independence & Conflict of Interest Policy

OncoGuides operates as an open-access public health and medical education initiative. To protect patient trust and objective clinical integrity:

Clinical Inquiries & Corrections

If you are an oncologist, clinical researcher, or patient advocacy leader with suggested updates or clinical feedback, please contact our review team at [email protected].